Vortioxetine: all 98 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• Vortioxetine for Newly Diagnosed GlioblastomaRecruitingNCT07284628Phase 2
• RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)RecruitingNCT07266545Phase 4
• A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive DisorderRecruitingNCT07204314Phase 3
• Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson DiseaseNot yet recruitingNCT06805266Phase 4
• Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal DementiaRecruitingNCT06604520Phase 2
• Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth SyndromeRecruitingNCT06025474Phase 3
• Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)RecruitingNCT05814640Phase 1/2
• Cognitive Effects of Adjuvant Vortioxetine in Early SchizophreniaRecruitingNCT04895488Phase 2/3
• Tolerability, Safety and Efficacy of VortioxetineRecruitingNCT04301492Phase 4
• Vortioxetine for Post-COVID-19 ConditionCompletedNCT05047952Phase 2Results posted
• Vortioxetine to Prevent Return of Symptoms in Children With DepressionTerminatedNCT05014919Phase 3Results posted
• A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg TabletsCompletedNCT03437564Phase 1Results posted
• Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive TrainingCompletedNCT03272711Phase 4Results posted
• THINC-it Vortioxetine - Sensitivity to ChangeCompletedNCT03053362Phase 2/3Results posted
• Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive DisorderCompletedNCT02972632Phase 4Results posted
• Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of VortioxetineTerminatedNCT02969876Phase 4Results posted
• Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy VolunteersCompletedNCT02932904Phase 4Results posted
• Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of AgeTerminatedNCT02871297Phase 3Results posted
• The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive DisorderCompletedNCT02749721Phase 4Results posted
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)CompletedNCT02709746Phase 3Results posted
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)CompletedNCT02709655Phase 3Results posted
• Vortioxetine for Posttraumatic Stress DisorderCompletedNCT02637895Phase 4Results posted
• Vortioxetine for Binge Eating DisorderCompletedNCT02528409Phase 2Results posted
• A Phase 3 Study of Lu AA21004 in Patients With Major Depressive DisorderCompletedNCT02389816Phase 3Results posted
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)CompletedNCT02371980Phase 4Results posted
• Investigating the Effect of Vortioxetine in Adult ADHD PatientsCompletedNCT02327013Phase 2Results posted
• Vortioxetine for Menopausal DepressionCompletedNCT02234362Phase 4Results posted
• Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic ImpairmentCompletedNCT02170220Phase 1Results posted
• Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian CountriesCompletedNCT01571453Phase 3Results posted
• Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive DisorderCompletedNCT01564862Phase 2Results posted
• Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety DisorderCompletedNCT01491035Phase 2Results posted
• A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous MedicationCompletedNCT01488071Phase 3Results posted
• Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive DisorderCompletedNCT01422213Phase 3Results posted
• Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual DysfunctionCompletedNCT01364649Phase 3Results posted
• Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive DisorderCompletedNCT01355081Phase 3Results posted
• Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT01323478Phase 3Results posted
• Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male AdultsCompletedNCT01299805Phase 1Results posted
• Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive DisorderCompletedNCT01255787Phase 2/3Results posted
• Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT01179516Phase 3Results posted
• Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT01163266Phase 3Results posted
• Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT01153009Phase 3Results posted
• Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension StudyCompletedNCT01152996Phase 3Results posted
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in AdultsCompletedNCT01140906Phase 3Results posted
• Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in AdultsCompletedNCT00839423Phase 2Results posted
• Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly PatientsCompletedNCT00811252Phase 3Results posted
• Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT00761306Phase 2Results posted
• Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.CompletedNCT00744627Phase 3Results posted
• Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT00735709Phase 3Results posted
• An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety DisorderCompletedNCT00734071Phase 3Results posted
• Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety DisorderCompletedNCT00731120Phase 3Results posted
• Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety DisorderCompletedNCT00730691Phase 3Results posted
• Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive DisorderCompletedNCT00707980Phase 3Results posted
• Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedNCT00694304Phase 3Results posted
• Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive DisorderCompletedNCT00672958Phase 3Results posted
• Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive DisorderCompletedNCT00672620Phase 3Results posted
• Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive DisorderCompletedNCT00635219Phase 3Results posted
• Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive EpisodesCompletedNCT00596817Phase 3Results posted
• Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot StudyCompletedNCT07000734Phase 2
• Postoperative Pain Management Following Laparoscopic CholecystectomyCompletedNCT06561438Phase 3
• Vortioxetine Adjunctive Treatment in Bipolar DepressionCompletedNCT05481957Phase 4
• Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating TabletsCompletedNCT05417087Phase 1
• Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive AbilitiesStatus unknownNCT05104918Phase 3
• Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing RadiotherapyStatus unknownNCT04818099Phase 3
• Vortioxetine for Treatment of Depressive Mood and Alcohol UseStatus unknownNCT04498897Phase 2
• Effect of Vortioxetine on Cognitive Symptoms in Patients With SchizophreniaStatus unknownNCT04456777Early Phase 1
• Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From DepressionCompletedNCT04448431Phase 4
• Vortioxetine in Patients With Depression and Early DementiaCompletedNCT04294654Phase 4
• Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in IndiaCompletedNCT04288895Phase 4
• Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)CompletedNCT04220996Phase 4
• Vortioxetine for the Treatment of Hoarding DisorderWithdrawnNCT04035850Phase 3
• Vortioxetine vs Sertraline in MexicansCompletedNCT03978286Phase 4
• A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy SubjectsCompletedNCT03884491Phase 1
• Study With Vortioxetine on Emotional Functioning in Patients With DepressionCompletedNCT03835715Phase 4
• MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA UsersStatus unknownNCT03830827Phase 4
• Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic AssessmentCompletedNCT03779789Phase 4
• Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With DepressionCompletedNCT03766867Phase 2
• Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar DepressionStatus unknownNCT03598868Phase 2
• Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 DiabetesWithdrawnNCT03580967Phase 4
• Substance Misuse To Psychiatric Disorders for CannabisCompletedNCT03485274Phase 2/3
• Cognitive Dysfunction in MDD PatientsStatus unknownNCT03187093Phase 4
• Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of AgeCompletedNCT03108625Phase 3
• Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive DisorderCompletedNCT02919501Phase 2
• Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)WithdrawnNCT02845349Phase 3
• Vortioxetine for MDD, Cognition, and Systemic Inflammatory BiomarkersWithdrawnNCT02637466Phase 4
• Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery DiseaseWithdrawnNCT02454426Early Phase 1
• A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic DisorderCompletedNCT02395510Phase 4
• Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and WomenCompletedNCT02386488Phase 1
• Adjunctive Vortioxetine in SchizophreniaActive, not recruitingNCT02357797Phase 4
• Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking VortioxetineCompletedNCT02332954Phase 4
• Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety DisorderStatus unknownNCT02294305Phase 4
• Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive DisorderCompletedNCT02279966Phase 3
• Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive DisorderCompletedNCT02279953Phase 3
• Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive DisorderCompletedNCT02272517Phase 3
• Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male SubjectsCompletedNCT02072278Phase 1
• Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and WomenCompletedNCT01676571Phase 1
• Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in ControlsCompletedNCT01607125Phase 1
• Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive DisorderCompletedNCT01395147Phase 3
• Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety DisorderCompletedNCT00788034Phase 3

← Vortioxetine overview